Your pharmacokinetic reasoning is actually sound. With a 168-hour half-life, the peak-to-trough ratio at steady state with once-weekly dosing is approximately 1.5:1 to 2:1. Splitting to twice weekly would reduce this ratio, giving flatter, more consistent levels.
However, there are several important considerations:
- The clinical trials were all conducted with once-weekly dosing. We have no RCT data on split dosing. The efficacy and safety profile we rely on is based on once-weekly administration.
- The GI side effects may actually be mediated more by local GI receptor activation than by plasma levels. Each injection causes a bolus of drug to reach GI receptors. Two smaller boluses might or might not be better tolerated than one larger one — we genuinely don't know.
- Practical downsides: Twice the injections, twice the injection site management, harder to maintain a consistent schedule, and if you're using compounded product, more frequent vial punctures which marginally increases contamination risk.
That said, some clinicians do prescribe split dosing for patients who experience late-week "wearing off" or who have severe peak-related nausea. It's off-label but not unreasonable.